{"schema_version":"secwatch.filing_event.v1","accession":"0001867096-23-000136","form_type":"8-K","ticker":"XERS","cik":"0001867096","company_name":"Xeris Biopharma Holdings, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.199590+00:00","generated_at":"2026-06-08T07:44:31.481100+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Record Q3 revenue $48.3M (+63% YoY); tightens FY23 guidance to $160-165M","bullets":["Total revenue $48.3M, up 63% YoY and 27% QoQ; product revenue $41.7M, up 41% YoY.","Gvoke net revenue $17.7M (+30% YoY); 58k prescriptions, 31% retail TRx glucagon share.","Recorlev net revenue $8.1M (+$5.6M vs prior year); patients on therapy up 203%.","Cash, cash equivalents and short-term investments $66.0M; expects cash flow breakeven in Q4 2023.","Tightened full-year 2023 revenue guidance from $155-165M to $160-165M."],"urls":{"canonical":"https://secwatch.observer/filing/0001867096-23-000136","json":"https://secwatch.observer/filing/0001867096-23-000136.json","markdown":"https://secwatch.observer/filing/0001867096-23-000136.md","text":"https://secwatch.observer/filing/0001867096-23-000136.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867096/000186709623000136/0001867096-23-000136-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867096/000186709623000136/xers-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T07:44:31.481100+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"752c41d8cba5cb5d22613f3be1e55d41f9871d15","claim":"Xeris Biopharma Holdings, Inc. reported the three and nine months ended September 30, 2023 results: revenue $48,320, net income Net Loss was $12.2 million, or $0.09 per share, for the three months ended September 30, 2023 and a net loss of $48.9 mi, EPS ($0.09) per share; ($0.36) per share. Guidance raised.","evidence_excerpt":"15,865 13,371 2,494 18.7 Recorlev 8,097 2,520 5,577 nm Product revenue, net 41,697 29,554 12,143 41.1 Royalty, contract and other revenue 6,623 171 6,452 nm Total revenue $ 48,320 $ 29,725 $ 18,595 62.6 nm - not meaningful Commercial Products • Gvoke® : Third quarter 2023 net revenue was $17.7 million as compared to $13.7 million in the third quarter of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867096/000186709623000136/0001867096-23-000136-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and nine months ended September 30, 2023"},{"label":"Revenue","value":"$48,320"},{"label":"Net income","value":"Net Loss was $12.2 million, or $0.09 per share, for the three months ended September 30, 2023 and a net loss of $48.9 mi"},{"label":"EPS","value":"($0.09) per share; ($0.36) per share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}